sr141716 has been researched along with Demyelinating Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, T; Fang, Y; Guo, J; Liao, H; Song, S; Sun, J; Yan, J; Zhang, L | 1 |
Colleoni, M; Costa, B; Croci, T; Giagnoni, G; Trovato, AE; Zarini, E | 1 |
2 other study(ies) available for sr141716 and Demyelinating Diseases
Article | Year |
---|---|
WIN55, 212-2 promotes differentiation of oligodendrocyte precursor cells and improve remyelination through regulation of the phosphorylation level of the ERK 1/2 via cannabinoid receptor 1 after stroke-induced demyelination.
Topics: Animals; Antimetabolites; Benzoxazines; Blotting, Western; Brain Ischemia; Bromodeoxyuridine; Cannabinoid Receptor Antagonists; Cell Differentiation; Cell Survival; Demyelinating Diseases; Immunohistochemistry; Indicators and Reagents; Male; MAP Kinase Signaling System; Microscopy, Electron; Morpholines; Myelin Basic Protein; Myelin Sheath; Naphthalenes; Oligodendroglia; Phosphorylation; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Stroke | 2013 |
Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve.
Topics: Analysis of Variance; Animals; Blotting, Western; Cannabinoid Receptor Antagonists; Constriction; Demyelinating Diseases; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Lipid Peroxides; Male; Mice; Mice, Knockout; Nerve Tissue Proteins; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitrites; Pain; Pain Measurement; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reaction Time; Receptors, Cannabinoid; Rimonabant; Sciatic Nerve; Sciatic Neuropathy; Staining and Labeling; Tumor Necrosis Factor-alpha | 2005 |